Citations

Mayo Clinic

Clear

31 citation(s) found for "Hasler, W L".

What's Coming Up Next? The Physiology of Gastroparesis and GLP-1 Agonists
Harer, Kimberly, Hasler, William L.

Annual Review of Physiology | November 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1146/annurev-physiol-040425-042341 | PMID 42994455 Get It

Glucagon-like peptide-1 (GLP-1) is an incretin to regulate glycemia, activates peripheral and central neural pathways to control appetite, and inhibits upper gut transit to reduce food intake. Peptide and nonpeptide GLP-1 receptor agonists (GLP-1RAs), as well as a combined GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), agonist are approved for type 2 diabetes, weight reduction, and other indications. GLP-1RA therapy can be complicated by upper gastrointestinal (GI) symptoms, including nausea and vomiting. Delayed gastric emptying secondary to GLP-1RAs may be influenced by drug pharmacokinetics, associated neuropathy, and development of tachyphylaxis with repeated dosing. A theoretical risk of pulmonary aspiration from retained gastric contents is concerning for patients undergoing anesthesia before endoscopy or surgery. Managing upper GI complications of GLP-1RA therapy includes diet modifications, antiemetic medications, and treatments that stimulate gastric emptying. Newer agents in testing include nonpeptide GLP-1RAs and GLP-1RAs acting in concert with GIP, glucagon, or other receptor-mediated pathways.
Cannabinoid Hyperemesis Syndrome
Venkatesan, Thangam , Hasler, William L. , Camilleri, Michael

JAMA | August 26, 2026 | Volume: 336 | Issue: 18 | Pages: 1642

10.1001/jama.2026.7873 | PMID 42647032 Get It

This JAMA Insights discusses cannabinoid hyperemesis syndrome, including pathophysiology, clinical presentation, and the epidemiology and risk factors.
Expert Clinical Consensus on Body Surface Gastric Mapping Phenotypes for Gastroduodenal Disorders: ‘Auckland Classification’ v1.0
Varghese, Chris , Dachs, Nicky , Schamberg, Gabriel , Abell, Thomas, Al‐Haddad, Mohammad, Angeli, Timothy R. , Ayubi, Homira , Bashashati, Mohammad , Bulat, Robert, Calder, Stefan, Cederwall, Christopher Brian, Chang, Bianca W. , Cheng, Leo K. , Clarke, John, Daker, Charlotte , Du, Peng, Erickson, Jon, Eriksson, Sven, Fikree, Asma , Foong, Daphne , Fox, Mark, Goenka, Mahesh, Haidry, R, Holtman, Gerald, Hobson, Anthony , Koloski, Natasha, Kuo, Braden, Law, Mikaela, Levinthal, D., Liu, Joy , Mathur, Prateek , Moshiree, Baharak, Ngo, Catherine, Nguyen, Linda, Oblizajek, Nicholas R. , Parkman, Henry P., Podboy, Alexander, Rezaie, Ali, Simmonds, Sam , Sivakumar, Jonathan , Sirimongkolkasem, Jarongkorn , Sonu, Irene, Stocker, Abigail, Sujka, Joseph, Tack, Jan, Weinstein, Douglas, Windsor, John, Zarate‐Lopez, Natalia, Andrews, Christopher N., O'Grady, Greg, Clarke, John O. , Angeli-Gordon, Timothy R , Chang, Bianca , Cheng, Leo K , Daker, Charlotte , Ghoshal, Uday C , Hasler, W L , Ho, Vincent , Keszthelyi, Daniel , Khalsa, Sahib S , Liu, Joy J , Neshatian, Leila , Oblizajek, Nicholas R , Pandanaboyana, Sanjay , Sharma, Amol , Wang, Xiao Jing , Xu, William , Varghese, Chris , Clarke, J , Schamberg, Gabriel , Al‐Haddad, Mohammad , Ayazi, Shahin , Bulat, Robert, Calder, Stefan , Cederwall, Chris, Du, Peng , Erickson, Jonathan C. , Ghoshal, Uday C. , Hasler, William L. , Hayee, Bu , Ho, Vincent , Huang, I‐Hsuan , Khalsa, Sahib S. , Kuo, Braden , Kunkel, David C. , Law, Mikaela , Levinthal, David J. , Moshiree, Baharak , Neshatian, Leila , Parkman, Henry P. , Podboy, Alexander , Rezaie, Ali , Sonu, Irene S. , Stocker, Abigail, Sujka, Joseph , Tack, Jan , Verdonk, Charles , Wang, Xiao Jing , Wongjarupong, Nicha , Xu, William , Andrews, Christopher N. , Gharibans, Armen A.

Neurogastroenterology & Motility | July 1, 2026 | Volume: 38 | Issue: 7 | Pages: No page available

10.1111/nmo.70377 | PMID 42381563 Get It

ABSTRACT Introduction Chronic gastroduodenal disorders remain challenging to manage, and new diagnostic approaches are needed to better delineate underlying causes and guide therapeutic decisions. Body Surface Gastric Mapping (BSGM) technologies combine high‐resolution gastric myoelectrical activity measurements with symptom and psychological profiling to provide mechanistic insights into gastric motor and sensory dysfunction. An International Working Group convened to derive the first consensus classification of BSGM phenotypes (the “Auckland Classification”). Methods A Technical Group conducted a systematic literature and clinical database review to identify objective test biomarkers and candidate disease mechanisms. Evidence was synthesized across 50 studies (primarily in gastroparesis, chronic nausea and vomiting, and functional dyspepsia), and BSGM phenotypes were mapped to existing treatment guidelines. Subsequently, iterative review and development of consensus was performed by a Consensus Group composed of international clinical experts familiar with BSGM. Eleven statements underlying the classification were then derived and circulated as a final survey to establish agreement. Results Six BSGM phenotypes were endorsed: three defined by myoelectrical abnormalities (Dysrhythmic, High Frequency, and Low Meal Response) and three by characteristic symptom associations (Sensorimotor, Continuous, and Delayed Onset Symptoms). Published studies plausibly linked these phenotypes to mechanisms including interstitial cell of Cajal depletion, vagal impairment, hypomotility, visceral hypersensitivity, gut‐brain dysregulation, and small bowel dysfunction. Phenotypes were also mapped to existing mechanism‐based treatment guidelines. Ten out of the eleven statements had > 80% agreement. Conclusions The Auckland Classification, derived by international consensus, presents a structured framework for BSGM‐defined patient phenotypes. Evidence and mechanism‐based treatment options are suggested for each phenotype to provide a foundation for research, further validation, and a pathway for integrating BSGM into clinical care.
Predominant Symptom in Gastroparesis: Relationships to Quality of Life, Treatments, and Outcome
Parkman, Henry P., Wilson, L., Grover, Madhusudan, Chumpitazi, Bruno P. , Burton‐Murray, Helen, Sarosiek, I, Moshiree, Baha, Preidis, Geoffrey A. , Shulman, R. J., Miriel, Laura , Shade, Dave, Kuo, Braden, McCallum, Richard W., Pasricha, Pankaj J. , Parkman, Henry P. , Parkman, H P , Hasler, William L. , Chumpitazi, Bruno P , Burton-Murray, Helen , Preidis, Geoffrey A , Wilson, Laura A., Grover, Madhusudan , Moshiree, Baha , Kuo, Braden , McCallum, Richard W. , Abell, Thomas L.

Neurogastroenterology & Motility | March 16, 2026 | Volume: 38 | Issue: 3 | Pages: No page available

10.1111/nmo.70287 | PMID 41833524 Get It

ABSTRACT Background Patients with gastroparesis (Gp) can have a variety of symptoms. Apart from use of prokinetics, symptomatic therapies for the predominant symptom (PrS) are used. Aims (1) To classify Gp patients based on their PrS; (2) To determine differences in Gp symptoms, gastric emptying (GE), quality of life (QOL), treatments, and symptom improvement among Gp patients with different PrS. Methods Gp patients were enrolled in a multicenter registry and followed for 96‐weeks. Patients recorded their PrS and completed questionnaires assessing symptoms and QOL at enrollment and at follow up visits. Results Of 1013 Gp patients (361 diabetic, 607 idiopathic, 45 post‐fundoplication), the PrS were nausea (31%), vomiting (20%), abdominal pain (20%), bloating (9%), fullness (4%), GERD (4%), constipation (3%). Abdominal pain was more often a PrS in idiopathics, whereas vomiting was more often a PrS in diabetics. QOL scores were lower in the abdominal pain PrS group. PrS was associated with greater use of directed symptomatic treatment (antiemetic agents and gastric electrical stimulation for nausea and vomiting, prokinetic agents for vomiting and fullness, and constipation medications for constipation). Of 555 patients followed over 48 weeks, GCSI improved by ≥ 1 in 26% overall, more often in patients with initial PrS of nausea (32%) and bloating (35%) and less often for initial PrS of fullness (13%) or abdominal pain (15%). Conclusions In Gp patients, the most common PrS were nausea, vomiting, and abdominal pain. PrS is associated with QOL, treatments utilized, and patient outcomes. Thus, the PrS of a patient with Gp provides useful information about their present condition and future outcome.
Accelerometric Assessment of Gastric Contractility Using the Atmo Wireless Motility Capsule
Abell, Thomas, Attaluri, Ashok, Chey, William D., Cline, Michael, Gearry, Richard B., Gibson, Peter R., Ho, Vincent, Lee, Allen A., Lembo, Anthony J, Masoud, Amir , McCallum, R, Moshiree, Baharak, Quigley, Eamonn M. M., Sanchez, Mayra, SAROSIEK, IRENE, Stocker, Abigail, Surjanhata, Brian , Kuo, Braden, Lembo, Anthony , Lee, Allen , Ho, Vincent , Hasler, William L. , Gibson, Peter R , Ho, Vincent , Lembo, Anthony , Surjanhata, Brian C , Lee, Allen A , Chey, William D. , Cline, Michael, Gearry, Richard B. , Moshiree, Baharak , Quigley, Eamonn M.M. , Rao, Satish R. , Thwaites, Phoebe A. , Zhou, Jerry , Kuo, Braden

Neurogastroenterology & Motility | February 12, 2026 | Volume: 38 | Issue: 2 | Pages: No page available

10.1111/nmo.70255 | PMID 41672928 Get It

ABSTRACT Background Patients with gastric dysmotility exhibit abnormal transit and reduced contractility, for which quantification is limited with current methodologies. The Atmo Capsule is a wireless motility capsule that measures regional gastrointestinal transit. We tested its technical capabilities to evaluate gastric contractility by detecting changes in capsule acceleration during transit. Methods Data from 91 healthy controls and 182 patients with suspected dysmotility who ingested the Atmo Capsule following a standardized protocol were included. Gastric emptying times (GET) ≥ 5 h were considered delayed. Contraction frequencies (cycles per minute [cpm]) and amplitudes (as arbitrary units [au]) were identified following Fast Fourier Transformation of accelerometer data using 5‐min windows and were assessed in 30‐min windows post‐ingestion (early gastric phase) and before gastric emptying (late gastric phase). Data were compared via ANOVA, using Bonferroni corrections, between healthy controls, patients with normal gastric emptying, and patients with delayed gastric emptying. Key Results Gastric emptying was delayed in 53/182 (29%) patients. Three cpm contraction frequencies were identified across both gastric phases in controls and patients. Contraction amplitudes did not differ between groups in the early gastric phase. In the late phase, mean amplitudes were lower in patients with delayed gastric emptying (6.4 au) compared with subjects with normal gastric emptying (controls, 9.7 au, p < 0.0001; patients, 8.6 au, p < 0.0001). Conclusions & Inference The Atmo Capsule enables precise quantification of gastric contraction profiles, permitting differentiation of normal from pathological motor patterns. Findings of this technical assessment support its potential for evaluating gastric physiology and detecting pathophysiological patterns of gastric dysmotility.
Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Frazier, Rosita , Hasler, William L. , Frazier, Rosita D , Hasler, W L

Expert Review of Gastroenterology & Hepatology | October 25, 2025 | Volume: 19 | Issue: 11 | Pages: 1181-1195

10.1080/17474124.2025.2579117 | PMID 41138239 Get It

Impact of Constipation Therapies on Severity of Gastroparesis and Constipation Symptoms in Relation to Gastric and Colonic Transit
Surjanhata, Brian , Moshiree, Baharak , Lee, Allen , McCallum, Richard W. , Sarosiek, Irene , Nguyen, Linda Anh B. , Schulman, Michael I., Wo, John M. , Parkman, Henry P. , Surjanhata, Brian C , Nguyen, Linda A , Hasler, William L. , Rao, Satish , Parkman, H P , Lee, Allen A , Kuo, Braden , Rao, Satish S.C.

Neurogastroenterology & Motility | March 11, 2025 | Volume: 37 | Issue: 6 | Pages: No page available

10.1111/nmo.70013 | PMID 40033166 Get It

ABSTRACTIntroductionStudies demonstrate an overlap of constipation with gastroparesis and functional dyspepsia, but the impact of treatments that target constipation on improving upper gastrointestinal (UGI) symptoms is unexplored. We quantified the effects of constipation medication therapies on UGI and constipation symptom severity in subjects presenting with symptoms of gastroparesis.MethodsFifty‐six subjects with symptoms of gastroparesis underwent concurrent wireless motility capsule and gastric emptying scintigraphy and were recommended to receive either a new medication therapy for constipation or a change in constipation therapy based on investigator interpretation of test results. Gastroparesis Cardinal Symptom Index (GCSI), upper abdominal pain, and constipation scores were compared between baseline and 6 months. Data were compared between delayed or non‐delayed gastric emptying and the presence or absence of slow colonic transit.Key ResultsSubjects with slow colonic transit had improvements in GCSI (p = 0.007) and constipation scores (p = 0.004) after treatment with a new or changed constipation medication, with the delayed emptying subgroup driving GCSI improvements (p = 0.004). Reductions in nausea/vomiting (p = 0.02) and early satiety/fullness subscores (p = 0.002) with trends to improved bloating/distention subscores (p = 0.06) were observed in this subgroup, but upper abdominal pain was unchanged. Subjects with normal colonic transit showed no improvement in GCSI scores regardless of gastric emptying status (p > 0.05).Conclusions and InferencesIdentifying and treating delayed colonic transit in gastroparetic (delayed gastric emptying) subjects improves global UGI symptoms as well as selected individual symptoms. Evaluation of whole gut motility as well as recognizing and managing extragastric delay may promote improved outcomes in these patients.Trial RegistrationClinicalTrials.gov: NCT02022826
Symptom Patterns in Adults With Cyclic Vomiting Syndrome: A 6‐Month Prospective Observational Study
Chen, Yaozhu J. , Rodriguez, Danielle , Richmond, Camilla A., Levinthal, David J. , Li, B U.K. , Petrakis, Ioannis , Coyne, Karin S. , Wu, Melody , Tack, Jan , Hasler, William L. , Levinthal, David J , Li, B U K , Venkatesan, Thangam , Tack, Jan , Rodriguez, Danielle, Venkatesan, Thangam

Neurogastroenterology & Motility | December 31, 2024 | Volume: 37 | Issue: 2 | Pages: No page available

10.1111/nmo.14974 | PMID 39737520 Get It

ABSTRACTBackgroundData are limited on the natural history and symptom patterns of cyclic vomiting syndrome (CVS), a disorder of gut–brain interaction characterized by recurrent stereotypical vomiting, retching, and nausea episodes.MethodsA 6‐month, observational, remote study prospectively assessed symptom patterns in adults with CVS using an electronic daily diary. Patients recorded their disease experience, including CVS symptoms and associated severity, in the daily diary. The study defined a CVS episode start as the first day of 5 or more vomiting and/or retching (V + R) events. Episode end was defined as the first day of ≥ 7 (prespecified main analysis) or ≥ 4 (sensitivity analysis) days without any diary V + R events.Key ResultsEighty‐eight of 93 (94.6%) enrolled patients (62 female; mean age, 37.7 years) had daily diary data recorded during the study; 61 (69.3%) patients had at least one episode. In the prespecified main analysis, 191 episodes (median, 0.6 per 30 diary days) were reported (median duration, 3.0 days); 17.8% of the episodes lasted > 10 days. In the sensitivity analysis, 248 episodes (median, 0.7 per 30 diary days) were reported (median duration, 2.0 days). Thirteen of 88 (14.8%) patients with diary data had interepisodic V + R (reported V + R events without meeting the threshold for study‐defined episode). Other CVS‐related (non‐V + R) symptoms (most frequently nausea, abdominal pain, and sweating) were reported more frequently during the episode versus the interepisodic period.Conclusions and InferencesThis prospective longitudinal study shows marked heterogeneity of CVS episodes and highlights the need to better define and characterize episodes in these patients.
Predictors of Outcomes After Gastric Peroral Endoscopic Myotomy for Refractory Gastroparesis: A Systematic Review
Varghese, Chris , Lim, Alexandria H. , Daker, Charlotte , Sebaratnam, Gabrielle , Andrews, Christopher N. , Hasler, William L. , O’Grady, Gregory , Lim, Alexandria , Gharibans, Armen A , Andrews, Christopher N , Hasler, W L , O'Grady, Gregory , Varghese, Chris , Gharibans, Armen A.

American Journal of Gastroenterology | November 14, 2024 | Volume: 120 | Issue: 6 | Pages: 1275-1284

10.14309/ajg.0000000000003213 | PMID 39733275 Get It

INTRODUCTION: Gastroparesis is a debilitating gastroduodenal disorder for which gastric peroral endoscopic myotomy (GPOEM) has emerged as an efficacious treatment option. However, response to GPOEM varies between 50% and 80%, such that preoperative predictors of treatment success are needed to guide patient selection. METHODS: We performed a systematic review to identify predictors of clinical and functional response to GPOEM among adult patients with gastroparesis (PROSPERO: CRD42023457359). MEDLINE, Embase, and CENTRAL databases were searched systematically for studies reporting outcomes after GPOEM in September 2023. A narrative synthesis of predictive factors on univariable and multivariable analysis was performed with consideration of response rates through meta-analysis and evaluation of discrimination if prognostic models were developed. Risk Of Bias In Non-randomized Studies - of Exposures (ROBINS-E) was used for risk of bias assessment. RESULTS: Of 1899 articles reviewed, 30 were included. The GPOEM response rate was 63.1% (95% confidence interval 56.3%–69.5%) with most studies defining clinical success on the basis of improvement in gastroparesis cardinal symptom index (87%, 26/30). Older age, shorter duration of gastroparesis, nondiabetic etiology, lower body mass index, and response to intrapyloric botulinum toxin were associated with positive response to GPOEM on multivariable analyses. Predictors on physiological tests such as EndoFLIP or gastric emptying scintigraphy were inconsistent. No prognostic models underwent external validation. DISCUSSION: Currently, there are limited reproducible predictors of response to GPOEM among patients with refractory gastroparesis. Robust prospective studies investigating scalable, reproducible, and actionable biomarkers of treatment response are required.
S729 Comparative Evaluation of Gas-Sensing Capsule and Wireless Motility Capsule for Transit Time Assessment in Motility Disorders
Cline, Michael, Masoud, Amir , McCallum, Richard W. , Moshiree, Baharak, Sanchez, Mayra, Sarosiek, Irene , Stocker, Abigail, Surjanhata, Brian , Chey, William D. , Kuo, Braden , Lee, Allen Ting Chun , Abell, Thomas L. , Attaluri, Ashok, Hasler, William L. , Ho, Vincent , Lembo, Anthony , Quigley, Eamonn M.M. , Rao, Satish S.C. , Zhou, Jerry

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S500-S501

10.14309/01.ajg.0001032284.18811.76 Get It